Drug Profile
Research programme: siRNA CNS disorder therapeutics - Quark Pharmaceuticals
Alternative Names: QP NR1Latest Information Update: 04 Feb 2021
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Neuroprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research CNS disorders
- No development reported Neuropathic pain
- Discontinued Neurodegenerative disorders; Spinal cord injuries
Most Recent Events
- 04 Feb 2021 Early research in CNS disorders in USA (unspecified route) (Quark Pharmaceuticals pipeline, February 2021)
- 28 Dec 2020 No recent reports of development identified for research development in Neuropathic-pain in USA
- 22 Nov 2016 Discontinued - Preclinical for Neurodegenerative disorders and Spinal-cord-injuries in USA (unspecified route) (Quark Pharmaceuticals pipeline, November 2016)